Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Travera Inc
Bio-Thera Solutions
Amgen
Iovance Biotherapeutics, Inc.
Dragonfly Therapeutics
Dragonfly Therapeutics
Immunocore Ltd
Seagen Inc.
AI Labs Group S.L
Merck Sharp & Dohme LLC
BioNTech SE
Endeavor Biomedicines, Inc.
Pfizer
Bristol-Myers Squibb
AI Labs Group S.L
AI Labs Group S.L
AI Labs Group S.L
Merck Sharp & Dohme LLC
Amgen
Adaptimmune
Hoffmann-La Roche
InxMed (Shanghai) Co., Ltd.
Daiichi Sankyo
Pierre Fabre Medicament
BioNTech SE
Pharmassist Ltd
Merck Sharp & Dohme LLC
Shanghai Juncell Therapeutics
Novartis
Highlight Therapeutics
C4 Therapeutics, Inc.
Lytix Biopharma AS
Bayer
Bristol-Myers Squibb
Incyte Corporation
Alaunos Therapeutics
Merck Sharp & Dohme LLC
Vedanta Biosciences, Inc.
Merck Sharp & Dohme LLC
Eisai Inc.
American Regent, Inc.
Merck Sharp & Dohme LLC
MacroGenics
Incyte Corporation
American Regent, Inc.
Istari Oncology, Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Arcus Biosciences, Inc.